Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it has entered into a definitive agreement to divest Sunosi® (solriamfetol), a dual-acting dopamine and norepinephrine reuptake inhibitor shown to improve wakefulness in adults living with excessive daytime sleepiness (EDS) due to narcolepsy or obstructive sleep apnea (OSA), to Axsome Therapeutics (Nasdaq: AXSM).
Jazz Pharmaceuticals Announces Agreement to Divest Sunosi® (solriamfetol) to Axsome Therapeutics
![thehealthco](https://thehealthco.info/wp-content/uploads/2022/03/Jazz-Pharmaceuticals-Announces-Agreement-to-Divest-Sunosi®-solriamfetol-to-Axsome-Therapeutics.jpg)